On Wednesday, October 7, Mark Zuckerberg and Priscilla Chan's nonprofit research institute Biohub announced that its Virtual Biology Initiative has grown from a $500 million solo commitment into a $1.8 billion coalition — with Google DeepMind, Isomorphic Labs, Meta, and two US federal agencies now on board.
Where the $1.8 billion comes from
The headline figure combines several pots. The US Department of Energy is putting more than $500 million over five years into lab measurement, modelling and computing through its Genesis Mission — drawing on national-lab supercomputers, cryo-electron microscopes and autonomous labs. The National Institutes of Health is contributing datasets and repositories built with more than $500 million of earlier federal spending, which Biohub will standardize into AI-ready training data. Google DeepMind, Isomorphic Labs and Meta are jointly committing $300 million. Biohub itself committed $500 million back in April. Organizing the science alongside them: the Allen Institute, Broad Institute, Gladstone Institutes, the Human Cell Atlas, the Human Protein Atlas and the Wellcome Sanger Institute — with Nvidia providing computing and software support.
The goal: a "virtual cell"
The target is a working AI model of a human cell — one detailed enough to predict what happens when a drug, a mutation or a disease hits it, without anyone running the experiment in a lab first. Biohub calls it the largest coordinated commitment to generating AI-ready biological data to date. Think flight simulator, but for medicine: researchers introduce a variable, the model predicts the outcome, and only the most promising leads move to expensive lab testing.
Why it matters
Drug development timelines currently stretch years and cost a fortune. A working virtual cell could compress that dramatically. And it's a sign of where AI's center of gravity is shifting — the same labs racing to build bigger chatbots are now pouring hundreds of millions into biology itself.
One honest catch
Not all of the $1.8 billion is new money — some of it counts existing commitments and past federal spending. And while the datasets will eventually be released publicly, the companies funding the work get an embargo period — a head start on the data — according to Biohub's head of science Alex Rives. The government-funded work running in parallel carries no such restrictions. Biohub says it will next approach drug companies and philanthropies.
AiPost's take: the AI race keeps expanding beyond chatbots into science itself. If a virtual cell works, it won't just change drug discovery — it will change what "AI progress" means.
Comments
Post a Comment